SCHEMBL2962372

SCHEMBL2962372

N[C@@H](CC(=O)O)C(=O)ON1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.38
GRM1 Q13255 2/20 0.32
DPP7 Q9UHL4 1/20 0.32
GABRR1 P24046 2/20 0.31
LMNA P02545 1/20 0.31
SLC22A6 Q4U2R8 1/20 0.31
GRM8 O00222 1/20 0.30
GRM6 O15303 1/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GSR P00390 1/20 0.30
CYP1A2 P05177 1/20 0.30
GRIK1 P39086 1/20 0.30
GRM5 P41594 1/20 0.30
GRIA1 P42261 1/20 0.30
GRIA2 P42262 1/20 0.30
GRIA3 P42263 1/20 0.30
SLC1A3 P43003 1/20 0.30
SLC1A2 P43004 1/20 0.30
SLC1A1 P43005 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18263746 0.92 DPP4 (0.40) DPP4GRM1DPP7
SCHEMBL18263743 0.77 DPP7 (0.33) DPP7
SCHEMBL28212548 0.77 DPP7 (0.33) DPP7
SCHEMBL22542447 0.74 ALDH1A1 (0.30) TDP1
SCHEMBL11794754 0.74 KMT2A (0.39) DPP4GRIK1GRIA1GRIA2GRIA4
SCHEMBL27740861 0.73
SCHEMBL1653844 0.73 SLC22A6 (0.39) DPP4GRM1GABRR1LMNASLC22A6
SCHEMBL30338047 0.72 SLC22A6 (0.38) DPP4GRM1GABRR1LMNASLC22A6
SCHEMBL3831500 0.72 SLC22A6 (0.38) DPP4GRM1GABRR1LMNASLC22A6
Hydrochloric Acid SCHEMBL11804611 0.72 SLC22A6 (0.38) DPP4GRM1GABRR1LMNASLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627868-B1 Aspartic ester functional compounds BAYER MATERIALSCIENCE LLC (US) 2007-12-19 EP claimed
EP-1627868-A2 Aspartic ester functional compounds Bayer MaterialScience LLC (US) 2006-02-22 EP claimed
US-20060011295-A1 Aspartic ester functional compounds BAYER MATERIAL SCIENCE LLC 2006-01-19 US claimed
US-7759452-B2 Aspartic ester functional compounds BAYER MATERIALSCIENCE LLC (US) 2010-07-20 US disclosed
US-7759452-B2 Aspartic ester functional compounds BAYER MATERIALSCIENCE LLC (US) 2010-07-20 US disclosed
US-20090142601-A1 ASPARTIC ESTER FUNCTIONAL COMPOUNDS COVESTRO LLC 2009-06-04 US disclosed
US-20090142601-A1 ASPARTIC ESTER FUNCTIONAL COMPOUNDS COVESTRO LLC 2009-06-04 US disclosed
EP-1627868-B1 Aspartic ester functional compounds BAYER MATERIALSCIENCE LLC (US) 2007-12-19 EP disclosed
CN-1865229-A Aspartic ester functional compounds BAYER MATERIALSCIENCE LLC (US) 2006-11-22 CN disclosed
EP-1627868-A3 Aspartic ester functional compounds Bayer MaterialScience LLC (US) 2006-05-31 EP disclosed
EP-1627868-A2 Aspartic ester functional compounds Bayer MaterialScience LLC (US) 2006-02-22 EP disclosed
EP-1627868-A2 Aspartic ester functional compounds Bayer MaterialScience LLC (US) 2006-02-22 EP disclosed
JP-2006028515-A FUNCTIONAL ASPARTIC ESTER BAYER MATERIAL SCIENCE LLC 2006-02-02 JP disclosed
US-20060011295-A1 Aspartic ester functional compounds BAYER MATERIAL SCIENCE LLC 2006-01-19 US disclosed
US-20060011295-A1 Aspartic ester functional compounds BAYER MATERIAL SCIENCE LLC 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060011295-A1 Aspartic ester functional compounds DDO, CDH1, ICAM1 DPP4 504/4885GRM1 125/4885DPP7 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.